Journal
DRUGS OF THE FUTURE
Volume 35, Issue 8, Pages 665-673Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2010.035.08.1513490
Keywords
-
Categories
Funding
- NIH-NCI [CA87025, CA32685]
- Midwest Athletes Against Childhood Cancer (MACC) Fund
- Abbie's Fund
- Evan Dunbar Foundation
- Crawdaddy Foundation
Ask authors/readers for more resources
Until recently, the prognosis for advanced neuroblastoma has been poor, with a high risk of recurrence after consolidation. Recently developed therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available